Alkermes Gets FDA Approval for Schizophrenia Treatment Aristada

Alkermes (ALKS), a biopharmaceutical company, said Tuesday the U.S. Food and Drug Administration has approved ARISTADA extended-release injectable suspension to treat schizophrenia. The company is preparing to launch the drug